The emerging role of GLP-1 receptor agonists in treating or preventing cancer

David J. Benjamin, Daniel D. Von Hoff · 2024

Read The emerging role of GLP-1 receptor agonists in treating or preventing cancer by David J. Benjamin, Daniel D. Von Hoff (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11810457.txt.

Description

David Benjamin and Daniel Von Hoff published a 2024 review of GLP-1 receptor agonists, the diabetes and weight-loss drugs, as possible cancer tools. Obesity feeds many cancers, and population data link these drugs with lower rates of obesity-related cancers in users. Lab studies add support: the drugs show antitumor activity on their own in cell and animal work.

Other preclinical studies suggest the drugs may help crack chemotherapy-resistant cancer cells. The authors argue the case is strong enough for randomized trials in both prevention and treatment. They frame the drugs as an intriguing second career for a metabolic medicine. The review is a call for proper clinical testing rather than a claim of proven benefit.

Catalog record

CREATORDavid J. Benjamin, Daniel D. Von Hoff
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE7 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11810457

Browse the full library · About the Tower of Babel